ATE234287T1 - Anregende aminosäuren antagonisten - Google Patents

Anregende aminosäuren antagonisten

Info

Publication number: ATE234287T1
Authority: AT; Austria
Prior art keywords: alkyl; chr; hydrogen; chem; phenyl
Prior art date: 1992-09-03

Application number

AT93306745T

Other languages

English (en)

Inventor

Macklin Brian Arnold

Nancy Kay Augenstein

Carl Franklin Bertsch

Marvin Martin Hansen

Allen Robert Harkness

Bret Eugene Huff

William Henry Walker Lunn

Michael John Martinelli

Paul Leslie Ornstein

Darryle Darwin Schoepp

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-09-03

Filing date

1993-08-25

Publication date

2003-03-15

1993-08-25 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2003-03-15 Application granted granted Critical

2003-03-15 Publication of ATE234287T1 publication Critical patent/ATE234287T1/de

Links

150000001413 amino acids Chemical class 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
230000004936 stimulating effect Effects 0.000 title 1
229910052739 hydrogen Inorganic materials 0.000 abstract 5
239000001257 hydrogen Substances 0.000 abstract 5
125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 5
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
125000002252 acyl group Chemical group 0.000 abstract 3
229910052717 sulfur Inorganic materials 0.000 abstract 3
125000000217 alkyl group Chemical group 0.000 abstract 2
125000003710 aryl alkyl group Chemical group 0.000 abstract 2
-1 hydroxy, amino, bromo, iodo Chemical group 0.000 abstract 2
229910052760 oxygen Inorganic materials 0.000 abstract 2
125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
NENLYAQPNATJSU-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline Chemical class C1NCCC2CCCCC21 NENLYAQPNATJSU-UHFFFAOYSA-N 0.000 abstract 1
229940123511 Excitatory amino acid receptor antagonist Drugs 0.000 abstract 1
208000012902 Nervous system disease Diseases 0.000 abstract 1
208000025966 Neurological disease Diseases 0.000 abstract 1
229910006069 SO3H Inorganic materials 0.000 abstract 1
125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
125000001309 chloro group Chemical group Cl* 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000000547 substituted alkyl group Chemical group 0.000 abstract 1
125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1
238000010189 synthetic method Methods 0.000 abstract 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Biochemistry (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Anesthesiology (AREA)
Otolaryngology (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Control Of El Displays (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

AT93306745T 1992-09-03 1993-08-25 Anregende aminosäuren antagonisten ATE234287T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/939,780 US5284957A (en)	1992-09-03	1992-09-03	Excitatory amino acid receptor antagonists

Publications (1)

Publication Number	Publication Date
ATE234287T1 true ATE234287T1 (de)	2003-03-15

Family

ID=25473721

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT93306745T ATE234287T1 (de)	1992-09-03	1993-08-25	Anregende aminosäuren antagonisten

Country Status (26)

Country	Link
US (7)	US5284957A (de)
EP (1)	EP0590789B9 (de)
JP (1)	JP3601840B2 (de)
KR (1)	KR100274367B1 (de)
CN (1)	CN1043762C (de)
AT (1)	ATE234287T1 (de)
AU (1)	AU656482B2 (de)
BR (1)	BR9303495A (de)
CA (2)	CA2484248A1 (de)
CZ (1)	CZ285049B6 (de)
DE (1)	DE69332754T2 (de)
DK (1)	DK0590789T3 (de)
ES (1)	ES2194844T3 (de)
FI (1)	FI933810L (de)
HU (2)	HU224015B1 (de)
IL (1)	IL106809A (de)
MX (1)	MX9305294A (de)
MY (1)	MY131442A (de)
NO (1)	NO304072B1 (de)
NZ (1)	NZ248513A (de)
PH (1)	PH31250A (de)
PL (1)	PL173809B1 (de)
PT (1)	PT590789E (de)
RU (1)	RU2117661C1 (de)
SG (1)	SG45319A1 (de)
ZA (1)	ZA936231B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2087812B1 (es) *	1993-07-02	1997-03-16	Lilly Co Eli	Derivados de decahidroisoquinolina utiles como antagonistas de los receptrores de los aminoacidos excitadores.
US5580877A (en) *	1994-04-25	1996-12-03	Merck Sharp & Dohme Ltd.	Pyrazolo-quinoline derivatives for treating cerebral ischemia
US5446051A (en) *	1994-05-31	1995-08-29	Eli Lilly And Company	Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
RU2164914C2 (ru) *	1995-11-13	2001-04-10	Хехст Акциенгезелльшафт	ЦИКЛИЧЕСКИЕ И ГЕТЕРОЦИКЛИЧЕСКИЕ N-ЗАМЕЩЕННЫЕ α-ИМИНОГИДРОКСАМОВЫЕ И КАРБОНОВЫЕ КИСЛОТЫ
US5723414A (en) *	1996-01-24	1998-03-03	Rohm And Haas Company	5-aryl-isoxazolinones and herbicidal use thereof
DE69716810T2 (de) *	1996-05-15	2003-02-27	Pfizer Inc., New York	2,3-Disubstituierte-(5,6)-heteroarylkondensierte-pyrimidin-4-one
KR100375155B1 (ko)	1996-05-15	2003-08-19	화이자 인코포레이티드	신규한2,3-이치환된-4(3에이치)-퀴나졸리논
HUP0002030A3 (en) *	1997-04-07	2002-01-28	Lilly Co Eli	Use of glur5 receptorantagonists for the treatment of pain
US6627755B1 (en)	1997-06-09	2003-09-30	Pfizer Inc	Quinazolin-4-one AMPA antagonists
IL125950A0 (en) *	1997-09-05	1999-04-11	Pfizer Prod Inc	Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
US6323208B1 (en)	1997-09-05	2001-11-27	Pfizer Inc	Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones
JP2002505288A (ja)	1998-03-02	2002-02-19	コセンシス，インコーポレイテッド	置換キナゾリンおよびアナログならびにそれらの使用
TW513301B (en) *	1999-03-01	2002-12-11	Novartis Ag	Pharmaceutical composition for treatment of neuropathic pain and affective and attention disorders
EP1200073B1 (de) *	1999-07-06	2007-01-10	Eli Lilly And Company	Selektive iglur5 rezeptorantagonisten zur behandlung der migräne
WO2001002367A2 (en) *	1999-07-06	2001-01-11	Eli Lilly And Company	Diester prodrugs of a decahydroisoquinoline-3-carboxylic acid
US6313159B1 (en)	1999-08-20	2001-11-06	Guilford Pharmaceuticals Inc.	Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors
AU2574801A (en)	1999-12-22	2001-07-03	Eli Lilly And Company	Selective iGLUR5 receptor antagonists
AU2002227020A1 (en) *	2001-01-05	2002-07-16	Eli Lilly And Company	Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
WO2003024453A1 (en) *	2001-01-05	2003-03-27	Eli Lilly And Company	Excitatory amino acid receptor antagonists
WO2002053556A2 (en) *	2001-01-05	2002-07-11	Eli Lilly And Company	Pyrrolidinylmethyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
KR20030066797A (ko) *	2001-01-05	2003-08-09	일라이 릴리 앤드 캄파니	흥분성 아미노산 수용체 길항제
US7205313B2 (en)	2001-01-05	2007-04-17	Eli Lilly And Company	Excitatory amino acid receptor antagonists
US6924294B2 (en)	2001-01-05	2005-08-02	Eli Lilly And Company	Excitatory amino acid receptor antagonists
GB0106858D0 (en) *	2001-03-20	2001-05-09	Perkins Engines Co Ltd	An accessory drive for driving an engine accessory
GB0128996D0 (en)	2001-12-04	2002-01-23	Novartis Ag	Organic compounds
US7091249B2 (en) *	2001-12-26	2006-08-15	University Of Iowa Research Foundation	Drugs for spinal anesthesia
WO2003082856A1 (en) *	2002-03-22	2003-10-09	Eli Lilly And Company	Isoquinoline-3-carboxylic acid derivatives as excitatory amino acid receptor antagonists
WO2003090780A1 (en) *	2002-04-26	2003-11-06	The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Direct cell target analysis
KR100757787B1 (ko) *	2002-04-26	2007-09-11	일라이 릴리 앤드 캄파니	진통제로서의 데카히드로이소퀴놀린-3-카르복실산의 에스테르 유도체
GB0222056D0 (en) *	2002-09-23	2002-10-30	Novartis Ag	Process for the manufacture of organic compounds
US20040152694A1 (en) *	2003-02-04	2004-08-05	Istvan Kurucz	Methods and compositions for treating inflammatory disorders of the airways
US20060220794A1 (en) *	2005-04-04	2006-10-05	Jeffrey Zhu	Phase modulation for backscatter transponders
WO2007101116A2 (en) *	2006-02-24	2007-09-07	The Trustees Of Columbia University In The City Of New York	Glur2 receptor modulators
US20080108622A1 (en) *	2006-10-19	2008-05-08	Eisenach James C	Combination therapy for the treatment of pain
US20080108603A1 (en) *	2006-10-19	2008-05-08	Eisenach James C	Combination therapy for the treatment of pain
US20090270508A1 (en) *	2007-02-23	2009-10-29	James Eric Gouaux	GluR2 receptor modulators
EP2338492A1 (de)	2009-12-24	2011-06-29	Universidad del Pais Vasco	Verfahren und Zusammensetzung zur Behandlung von Alzheimer
CN101812031A (zh) *	2010-04-29	2010-08-25	南通市华峰化工有限责任公司	一种5-羟烷基四氮唑的高压生产方法
WO2013134562A1 (en)	2012-03-09	2013-09-12	Inception 2, Inc.	Triazolone compounds and uses thereof
AU2013363398B2 (en)	2012-12-20	2017-06-01	Tempest Therapeutics, Inc.	Triazolone compounds and uses thereof
TWI593692B (zh) *	2013-03-12	2017-08-01	美國禮來大藥廠	四氫吡咯并噻嗪化合物
US9776976B2 (en)	2013-09-06	2017-10-03	Inception 2, Inc.	Triazolone compounds and uses thereof
CA3066711A1 (en)	2017-07-31	2019-02-07	Novartis Ag	Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
MX2022016223A (es)	2020-07-02	2023-02-23	Sea Pharmaceuticals Llc	Composiciones farmaceuticas de acido 6-(2-(2h-tetrazol-5-il)etil)- 6-fluorodecahidroisoquinolina-3-carboxilico y derivados de ester del mismo.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK704488D0 (da) *	1988-12-19	1988-12-19	Novo Industri As	Nye n-substituerede azaheterocykliske carboxylsyrer
US4897490A (en) *	1987-02-25	1990-01-30	Bristol-Meyers Company	Antihypercholesterolemic tetrazole compounds
US4824959A (en) *	1988-02-18	1989-04-25	Bristol-Myers Company	Intermediates for antihypercholesterolemic tetrazole compounds
US4902695A (en) *	1989-02-13	1990-02-20	Eli Lilly And Company	Excitatory amino acid receptor antagonists
US5192751A (en) *	1992-07-24	1993-03-09	Eli Lilly And Company	Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence

1992
- 1992-09-03 US US07/939,780 patent/US5284957A/en not_active Expired - Lifetime
1993
- 1993-08-25 ES ES93306745T patent/ES2194844T3/es not_active Expired - Lifetime
- 1993-08-25 DE DE69332754T patent/DE69332754T2/de not_active Expired - Lifetime
- 1993-08-25 PT PT93306745T patent/PT590789E/pt unknown
- 1993-08-25 AT AT93306745T patent/ATE234287T1/de active
- 1993-08-25 US US08/111,747 patent/US5399696A/en not_active Expired - Lifetime
- 1993-08-25 DK DK93306745T patent/DK0590789T3/da active
- 1993-08-25 EP EP93306745A patent/EP0590789B9/de not_active Expired - Lifetime
- 1993-08-25 CZ CZ931745A patent/CZ285049B6/cs not_active IP Right Cessation
- 1993-08-25 SG SG1996003438A patent/SG45319A1/en unknown
- 1993-08-25 ZA ZA936231A patent/ZA936231B/xx unknown
- 1993-08-26 CA CA002484248A patent/CA2484248A1/en not_active Abandoned
- 1993-08-26 IL IL10680993A patent/IL106809A/en not_active IP Right Cessation
- 1993-08-26 CA CA002104909A patent/CA2104909C/en not_active Expired - Lifetime
- 1993-08-26 BR BR9303495A patent/BR9303495A/pt not_active Application Discontinuation
- 1993-08-27 NZ NZ248513A patent/NZ248513A/en unknown
- 1993-08-27 PH PH46762A patent/PH31250A/en unknown
- 1993-08-30 HU HU9302453A patent/HU224015B1/hu active IP Right Grant
- 1993-08-31 AU AU46003/93A patent/AU656482B2/en not_active Expired
- 1993-08-31 MX MX9305294A patent/MX9305294A/es unknown
- 1993-08-31 RU RU93049265A patent/RU2117661C1/ru active
- 1993-08-31 NO NO933100A patent/NO304072B1/no not_active IP Right Cessation
- 1993-08-31 FI FI933810A patent/FI933810L/fi unknown
- 1993-09-01 KR KR1019930017398A patent/KR100274367B1/ko not_active Expired - Lifetime
- 1993-09-01 JP JP21744193A patent/JP3601840B2/ja not_active Expired - Lifetime
- 1993-09-01 CN CN93117627A patent/CN1043762C/zh not_active Expired - Lifetime
- 1993-09-01 PL PL93300250A patent/PL173809B1/pl unknown
- 1993-09-01 MY MYPI93001753A patent/MY131442A/en unknown
1994
- 1994-11-21 US US08/343,079 patent/US5637712A/en not_active Expired - Lifetime
1995
- 1995-06-01 US US08/456,577 patent/US5648492A/en not_active Expired - Lifetime
- 1995-06-01 US US08/456,439 patent/US5670516A/en not_active Expired - Lifetime
- 1995-06-01 US US08/457,556 patent/US5606062A/en not_active Expired - Lifetime
- 1995-06-01 US US08/457,766 patent/US5675008A/en not_active Expired - Lifetime
- 1995-06-22 HU HU95P/P00401P patent/HU211992A9/hu unknown

Also Published As

Publication number	Publication date
CN1043762C (zh)	1999-06-23
NO933100L (no)	1994-03-04
HK1013989A1 (en)	1999-09-17
EP0590789A1 (de)	1994-04-06
FI933810A7 (fi)	1994-03-04
AU4600393A (en)	1994-03-10
DK0590789T3 (da)	2004-03-22
NZ248513A (en)	1996-02-27
PT590789E (pt)	2003-07-31
SG45319A1 (en)	1998-01-16
US5648492A (en)	1997-07-15
MY131442A (en)	2007-08-30
US5284957A (en)	1994-02-08
HU224015B1 (hu)	2005-04-28
PH31250A (en)	1998-06-18
US5637712A (en)	1997-06-10
CZ285049B6 (cs)	1999-05-12
JPH06199802A (ja)	1994-07-19
PL173809B1 (pl)	1998-05-29
ZA936231B (en)	1995-02-27
NO304072B1 (no)	1998-10-19
HU9302453D0 (en)	1993-11-29
EP0590789B1 (de)	2003-03-12
US5670516A (en)	1997-09-23
RU2117661C1 (ru)	1998-08-20
HU211992A9 (en)	1996-01-29
FI933810L (fi)	1994-03-04
DE69332754T2 (de)	2004-06-17
KR100274367B1 (ko)	2000-12-15
HUT65228A (en)	1994-05-02
CZ174593A3 (en)	1994-03-16
CA2484248A1 (en)	1994-03-04
CA2104909C (en)	2005-01-11
DE69332754D1 (de)	2003-04-17
ES2194844T3 (es)	2003-12-01
CA2104909A1 (en)	1994-03-04
US5399696A (en)	1995-03-21
US5606062A (en)	1997-02-25
CN1091129A (zh)	1994-08-24
BR9303495A (pt)	1994-03-22
EP0590789B9 (de)	2004-02-04
FI933810A0 (fi)	1993-08-31
KR940007021A (ko)	1994-04-26
NO933100D0 (no)	1993-08-31
IL106809A (en)	1999-03-12
MX9305294A (es)	1994-06-30
AU656482B2 (en)	1995-02-02
JP3601840B2 (ja)	2004-12-15
US5675008A (en)	1997-10-07

Legal Events

Date

Code

Title

Description

2004-02-15

UEP

Publication of translation of european patent specification

Ref document number: 0590789

Country of ref document: EP

Publication	Publication Date	Title
ATE234287T1 (de)	2003-03-15	Anregende aminosäuren antagonisten
DE3762618D1 (de)	1990-06-13	Amidderivate.
LU90562I2 (fr)	2000-06-05	Acides imidazoalc-noiques
ATE141606T1 (de)	1996-09-15	Cephemverbindungen und verfahren zu ihrer herstellung
ATE84545T1 (de)	1993-01-15	Derivate des alpha-anp und ihre herstellung.
ATE116974T1 (de)	1995-01-15	5- piperazinylalkyl-1,5-benzothiazepinone verwendbar als calciumantagonisten.
DK1178047T3 (da)	2004-05-24	Diazabicyclooctanderivater og terapeutiske anvendelser deraf
DE68903019D1 (de)	1992-11-05	4,5,6,7-tetrahydroisothiazolo (4,5-c)pyridin-derivate und isomere.
HU895648D0 (en)	1990-01-28	Process for the preparation of n,n-disubstituted diaryl-alkancarboxylic acid amide derivatives and pharmaceutical compositions containing such compounds
HUT57211A (en)	1991-11-28	Process for producing pyrrolo-pyrimidine derivatives, pharmaceutically acceptable salts thereof and pahrmaceutical compositions containing them as active components
ATE113950T1 (de)	1994-11-15	4,5,6,11-tetrahydrobenzo(6,7>-cycloocta(1,2- b>thiophen-6,11-imine und 6,11-dihydrobenzo(6,7>- cycloocta(1,2-b>thiophen-6,11-imine.
PT911336E (pt)	2002-04-29	Derivados do acido piridonacarboxilico e intermediarios para a sua sintese
ATE108444T1 (de)	1994-07-15	3-isoxazolonderivate, ihre herstellung und ihre anwendung in der therapeutik.
IT1274040B (it)	1997-07-14	Composizioni farmaceutiche per la prevenzione e/o il trattamento di disturbi gastrointestinali inclusa l'ulcera